Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Medite Cancer Diagnostics, Inc. | v419260_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
| Date of report (Date of earliest event reported) | August 27, 2015 |
MEDITE CANCER DIAGNOSTICS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
| 333-143570 | 36-4296006 |
| (Commission File Number) | (IRS Employer Identification No.) |
| 4203 SW 34th St. | |
| Orlando, FL | 32811 |
| (Address of Principal Executive Offices) | (Zip Code) |
(407) 996-9630
(Registrant’s telephone number, including area code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 1.01 Entry into a Material Definitive Agreement
On August 25, 2015, MEDITE Cancer Diagnostics, Inc., a Delaware corporation (the "Company") entered into an agreement with its Mexican Distributor, ATDYE, for the delivery of 31 MEDITE tissue staining machines, with a total retail value of approximately $600,000 to the Company. ATYDE has ordered 13 units of MEDITE’s Programmable Slide Stainer TST44 and 18 units of MEDITE Continuous Linear Stainer COT20. On August 25, 2015, the Company also delivered the first 10 units of the new developed manual microtome M380 to our Chinese partner UNIC Medical.
Item 9.01 Financial Statements and Exhibits.
Exhibit 99.1. Press Release
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| MEDITE CANCER DIAGNOSTICS, INC. | ||
| Date: August 27, 2015 | By: | /s/ Michaela Ott |
| Michaela Ott | ||
| Chief Executive Officer | ||
| 2 |